Virtual Screening and Molecular Design Based on Hierarchical Qsar Technology

Challenges and Advances in Computational Chemistry and Physics

Volumn 8, Issue , 2010, Pages 127-176

  Kuz’min, Victor E ^a   Artemenko, A G ^a   Muratov, Eugene N ^a   Polischuk, P G ^a   Ognichenko, L N ^a   Liahovsky, A V ^a   Hromov, A I ^a   Varlamova, E V ^a  

^a A V BOGATSKY PHYSICO CHEMICAL INSTITUTE   (Ukraine)

Author keywords

HiT QSAR; Simplex representation; SiRMS

Indexed keywords

EID: 85073148043     PISSN: 25424491     EISSN: 25424483     Source Type: Book Series    
DOI: 10.1007/978-1-4020-9783-6_5     Document Type: Chapter

References (94)

1. Ooms F (2000) Molecular modeling and computer aided drug design. Examples of their applications in medicinal chemistry. Curr Med Chem 7:141–158
2. Thomas G (2008) Medicinal chemistry: An introduction, 2nd edn John Wiley & Sons Inc, New York
3. ′-(bis-5-nitropyrimidyl)dispirotripiperazine derivatives for cytotoxicity and antiherpetic activity allows the prediction of new highly active compounds. J Antimicrob Chemother 60:68–77
4. Bailey TR, Diana GD, Kowalczyk PJ et al. (1992) Antirhinoviral activity of heterocyclic analogs of win 54954. J Med Chem 35:4628–4633
5. Butina D, Gola JMR (2004) Modeling aqueous solubility. J Chem Inf Comp Sci 43:837–841
6. de Jonge MR, Koymans LM, Vinkers HM et al. (2005) Structure based activity prediction of HIV-1 reverse transcriptase inhibitors. J Med Chem 48:2176–2183
7. Jenssen H, Gutteberg TJ, Lejon T (2005) Modelling of anti-HSV activity of lactoferricin analogues using amino acid descriptors. J Pept Sci 11:97–103
8. Kovatcheva A, Golbraikh A, Oloff S et al. (2004) Combinatorial QSAR of ambergris fragrance compounds. J Chem Inf Comp Sci 44:582–595
9. Kubinyi H (1990) Quantitative structure–activity relationships (QSAR) and molecular modeling in cancer research. J Cancer Res Clin Oncol 116:529–537
10. Kuz’min VE, Artemenko AG, Lozitska RN et al. (2005) Investigation of anticancer activity of macrocyclic Schiff bases by means of 4D-QSAR based on simplex representation of molecular structure. SAR QSAR Environ Res 16:219–230
11. Kuz’min VE, Artemenko AG, Muratov EN et al. (2007) Quantitative structure–activity relationship studies of [(biphenyloxy)propyl]isoxazole derivatives – human rhinovirus 2 replication inhibitors. J Med Chem 50:4205–4213
12. Muratov EN, Artemenko AG, Kuz’min VE et al. (2005) Investigation of anti-influenza activity using hierarchic QSAR technology on the base of simplex representation of molecular structure. Antivir Res 65:A62–A63
13. Verma RP, Hansch C (2006) Chemical toxicity on HeLa cells. Curr Med Chem 13:423–448
14. Zhang S, Golbraikh A, Tropsha A (2006) The development of quantitative structure–binding affinity relationship (QSBR) models based on novel geometrical chemical descriptors of the protein–ligand interfaces. J Med Chem 49:2713–2724
15. Selassie CD (2003) History of QSAR. In: Abraham DJ (ed) Burger’s medicinal chemistry and drug discovery. Wiley, New York, p 960
16. Cramer RD, Patterson DI, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape binding to carrier proteins. J Am Chem Soc 110:5959–5967
17. Doweyko AM (1988) The hypothetical active site lattice. An approach to modeling active sites from data on inhibitor molecules. J Math Chem 31:1396–1406
18. Klebe G, Abraham U, Mietzner T (1994) Molecular similarity indeces in comparative ana-ysis (CoMSIA) of molecules to correlate and predict their biological activity. J Med Chem 37:4130–4146
19. Kuz’min VE, Artemenko AG, Kovdienko NA et al. (2000) Lattice model for QSAR studies. J Mol Model 6:517–526
20. Seel M, Turner DB, Wilett P (1999) HQSAR – a highly predictive QSAR technique based on molecular holograms. QSAR 18:245–252
21. Pavan M, Consonni V, Gramatica P et al. (2006) New QSAR modelling approach based on ranking models by genetic algorithms – variable subset selection (GA-VSS). In: Brüggeman R, Carlsen L (eds) Partial order in environmental sciences and chemistry. Springer Berlin Heidelberg, Berlin, pp 181–217
22. Kuz’min VE, Muratov EN, Artemenko AG et al. (2008) The effect of nitroaromatics composition on theirs toxicity in vivo. 1D QSAR research. Chemosphere 72:1373–1380
23. Baurin N, Mozziconacci JC, Arnoult E et al. (2004) 2D QSAR consensus prediction for high-throughput virtual screening. An application to COX-2 inhibition modeling and screening of the NCI database. J Chem Inf Model 44:276–285
24. Vedani A, Dobler M (2000) Multi-dimensional QSAR in drug design. Progress in Drug Res 55: 107–135
25. Artemenko A, Kuz’min V, Muratov E et al. (2007) Molecular design of active antiherpetic compounds using hierarchic QSAR technology. Antivir Res 74:A76
26. Artemenko A, Muratov E, Kuz’min V et al. (2006) Molecular design of novel antimicrobial agents on the base of 4-thiazolidone derivatives. Clin Microbiol Infec 12:1557
27. Artemenko A, Muratov E, Kuz’min V et al. (2006) Influence of artifical ribonucleases structure on their anti-HIV activity. Antivir Res 70:A43
28. Artemenko AG, Kuz’min VE, Muratov EN et al. (2005) Investigation of antiherpetic activity using hierarchic QSAR technology on the base of simplex representation of molecular structure. Antivir Res 65:A77
29. Kuz’min VE, Artemenko AG, Lozitsky VP et al. (2002) The analysis of structure-anticancer and antiviral activity relationships for macrocyclic pyridinophanes and their analogues on the basis of 4D QSAR models (simplex representation of molecular structure). Acta Biochim Polon 49: 157–168
30. Kuz’min VE, Artemenko AG, Muratov EN et al. (2007) QSAR analysis of anti-coxsackievirus B3 nancy activity of 2-amino-3-nitropyrazole[1,5-α]pyrimidines by means of simplex approach. Antivir Res 74:A49–A50
31. Kuz’min VE, Artemenko AG, Muratov EN et al. (2005) The hierarchical QSAR technology for effective virtual screening and molecular design of the promising antiviral compounds. Antivir Res 65:A70–A71
32. Kuz’min VE, Artemenko AG, Polischuk PG et al. (2005) Hierarchic system of QSAR models (1D-4D) on the base of simplex representation of molecular structure. J Mol Model 11:457–467
33. Muratov E, Artemenko A, Kuz’min V et al. (2006) Computational design of the new antimicrobials based on the substituted crown ethers. Clin Microbiol Infec 12:1558
34. Muratov EN (2004) Quantitative evaluation of the structural factors influence on the properties of nitrogen-, oxygen-and sulfur-containing macroheterocycles. National Academy of Sciences of Ukraine, A.V. Bogatsky Physical-Chemical Institute, Odessa, p 202
35. Muratov EN, Kuz’min VE, Artemenko AG et al. (2006) QSAR studies demonstrate the influence of structure of [(biphenyloxy)propyl]isoxazole derivatives on inhibition of coxsackievirus B3 (CVB3) replication. Antivir Res 70:A77
36. Kuz’min VE, Artemenko AG, Muratov EN (2008) Hierarchical QSAR technology on the base of simplex representation of molecular structure. J Comp Aid Mol Des 22:403–421
37. Kuz’min VE, Muratov EN, Artemenko AG et al. (2008) The effects of characteristics of substituents on toxicity of the nitroaromatics: HiT QSAR study. J Comp Aid Mol Des 22:747–759. doi:10.1007/s10822-10008-19211-x
38. QSAR, Expert, Group (2004) The report from the expert group on (quantitative) structure–activity relationships [(Q)SARs] on the principles for the validation of (Q)SARs. In: OECD series on testing and assessment. Organisation for Economic Co-operation and Development, Paris, p 206
39. Kuz’min VE (1995) About homo-and heterochirality of dissymetrical tetrahedrons (chiral sim-plexes). Stereochemical tunneling. Zh Strucur Khim (in Russ) 36:873–878
40. Jolly WL, Perry WB (1973) Estimation of atomic charges by an electronegativity equalization procedure calibration with core binding energies. J Am Chem Soc 95:5442–5450
41. Wang R, Fu Y, Lai L (1997) A new atom-additive method for calculating partition coefficients. J Chem Inf Comp Sci 37:615–621
42. Ioffe BV (1983) Chemistry refractometric methods, 3 ed. Himiya, Leningrad
43. Cahn RS, Ingold CK, Prelog V (1966) Specification of molecular chirality. Angew Chem Int Ed 5:385–415
44. Burkert U, Allinger N (1982) Molecular mechanics. ACS Publication, Washington, DC
45. Hodges G, Roberts DW, Marshall SJ et al. (2006) Defining the toxic mode of action of ester sulphonates using the joint toxicity of mixtures. Chemosphere 64:17–25
46. Kuz’min VE, Muratov EN, Artemenko AG et al. (2009) Consensus QSAR modeling of phosphor-containing chiral AChE inhibitors. J Comp Aid Mol Des 28:664–677
47. Hyperchem 7.5 software. Hypercube, Inc. 1115 NW 4th Street, Gainesville, FL 32601, USA
48. Kuz’min VE, Artemenko AG, Kovdienko NA et al. (1999) Lattice models of molecules for solution of QSAR tasks. Khim-Pharm Zhurn (in Russ) 9:14–20
49. Kuz’min VE, Beresteckaja EL (1983) The program for calculation of atom charges using the method of orbital electronegativities equalization. Zh Struct Khimii (in Russ) 24:187–188
50. Croizet F, Langlois MH, Dubost JP et al. (1990) Lipophilicity force field profile: An expressive visualization of the lipophilicity molecular potential gradient. J Mol Graphics 8:53
51. Artemenko AG, Kovdienko NA, Kuzmin VE et al. (2002) The analysis of “structure-anticancer activity” relationship in a set of macrocyclic pyridinophanes and their acyclic analogues on the basis of lattice model of molecule using fractal parameters. Exp Oncol 24:123–127
52. Lozitsky VP, Kuz’min VE, Artemenko AG et al. (2000) The analysis of structure–anti-influenza relationship on the basis molecular lattice model for macrocyclic piridino-phanes and their analogs. Antivir Res 50:A85
53. Marple SL Jr (1987) Digital spectral analysis with applications. Prentice-Hall Inc., Englewood Cliffs, NJ
54. Kuz’min VE, Trigub LP, Shapiro YE et al. (1995) The parameters of shape of peptide molecules as a descriptors in the QSAR tasks. Zh Struct Khimii (in Russ) 36:509–517
55. Breiman L, Friedman JH, Olshen RA et al. (1984) Classification and regression trees. Wadsworth, Belmont
56. Carhart RE, Smith DH, Venkataraghavan R (1985) Atom pairs as molecular features in structure– activity studies. Definition and application. J Chem Inf Comput Sci 25:64–73
57. Vitiuk NV, Kuz’min VE (1994) Mechanistic models in chemometrics for the analysis of multidimensional data of researches. Analogue of dipole-moments method in the structure(composition)– property relationships analysis. ZhAnalKhimii 49:165–167
58. Ferster E, Renz B (1979) Methoden der Korrelations und Regressionanalyse. Verlag Die Wirtschaft, Berlin
59. Topliss JG, Costello RJ (1972) Chance correlations in structure–activity studies using multiple regression analysis. J Med Chem 15:1066–1068
60. Kubinyi H (1996) Evolutionary variable selection in regression and PLS analyses. J Chemometr 10:119–133
61. Lindgren F, Geladi P, Rannar S et al. (1994) Interactive variable selection (IVS) for PLS. Part 1: Theory and algorithms. J Chemometr 8:349–363
62. Rannar S, Lindgren F, Geladi P et al. (1994) A PLS kernel algorithm for data sets with many variables and fewer objects. Part 1: Theory and algorithm. J Chemometr 8:111–125
63. Rogers D, Hopfinger AJ (1994) Application of genetic function approximation to quantitative structure–activity relationships and quantitative structure–property relationships. J Chem Inf Comp Sci 34:854–866
64. Wold S, Antti H, Lindgren F et al. (1998) Orthogonal signal correction of nearinfrared spectra. Chemometrics Intell Lab Syst 44:175–185
65. Trygg J, Wold S (2002) Orthogonal projections to latent structures (O-PLS). J Chemometr 16: 119–128
66. Cronin MTD, Schultz TW (2003) Pitfalls in QSAR. J Mol Struct (Theochem) 622:39–51
67. Zhang S, Golbraikh A, Oloff S et al. (2006) A novel automated lazy learning QSAR (ALL-QSAR) approach: Method development, applications, and virtual screening of chemical databases using validated ALL-QSAR models. J Chem Inf Model 46:1984–1995
68. Neter J, Kutner MH, Wasseman W et al. (1996) Applied linear statistical models. McGraw-Hill, New York
69. Meloun M, Militku J, Hill M et al. (2002) Crucial problems in regression modelling and their solutions. Analyst 127:433–450
70. Jaworska J, Nikolova-Jeliazkova N, Aldenberg T (2005) QSAR applicability domain estimation by projection of the training set in descriptor space: A review. Altern Lab Anim 33:445–459
71. Östergard PRJ (2002) A fast algorithm for the maximum clique problem. Discrete Appl Math 120:195–205
72. Bodor N, Buchwald P (2000) Soft drug design: General principles and recent applications. Med Res Rev 20:58–101
73. Sutherland JJ, O’Brien LA, Weaver DF (2004) A comparison of methods for modeling quantitative structure–activity relationships. J Med Chem 47:5541–5554
74. Heritage TV, Ferguson AM, Turner DB et al. (1998) EVA: A novel theoretical descriptor for QSAR studies. Persp Drug Disc Des 11:381–398
75. Barnard DL (2006) Current status of anti-picornavirus therapies. Curr Pharm Des 12:1379–1390
76. Patick AK (2006) Rhinovirus chemotherapy. Antivir Res 71:391–396
77. Rotbart HA (2002) Treatment of picornavirus infections. Antivir Res 53:83–98
78. Binford SL, Maldonado F, Brothers MA et al. (2005) Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother 49:619–626
79. Conti C, Mastromarino P, Goldoni P et al. (2005) Synthesis and anti-rhinovirus properties of fluoro-substituted flavonoids. Antivir Chem Chemother 16:267–276
80. Cutri CC, Garozzo A, Siracusa MA et al. (2002) Synthesis of new 3-methylthio-5-aryl-4-isothiazolecarbonitriles with broad antiviral spectrum. Antiviral Res 55:357–368
81. Diana GD, Cutcliffe D, Oglesby RC et al. (1989) Synthesis and structure–activity studies of some disubstituted phenylisoxazoles against human picornavirus. J Med Chem 32:450–455
82. Dragovich PS, Prins TJ, Zhou R et al. (2002) Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics. J Med Chem 45:1607–1623
83. Gaudernak E, Seipelt J, Triendl A et al. (2002) Antiviral effects of pyrrolidine dithiocarbamate on human rhinoviruses. J Virol 76:6004–6015
84. Kaiser L, Crump CE, Hayden FG (2000) In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antiviral Res 47:215–220
85. Suchachev DV, Pivina TS, Shliapochnikov VA et al. (1993) Investigation of quantitative “structure-shock-sensitivity” relationships for organic polynitrous compounds. Dokl RAN (in Russ) 328:50–57
86. Kuz’min VE, Lozitsky VP, Kamalov GL et al. (2000) The analysis of “structure–anticancer activity” relationship in a set of macrocyclic 2,6-bis (2-and 4-formylaryloxymethyl) pyridines Schiff bases. Acta Biochim Polon 47:867–875
87. Kuz’min VE, Muratov EN, Artemenko AG et al. (2008) The effect of nitroaromatics’ composition on their toxicity in vivo: Novel, efficient non-additive 1D QSAR analysis. Chemosphere 72(9):1373–1380. doi:10.1016/j.chemosphere.2008.1004.1045
88. Katritzky AR, Oliferenko P, Oliferenko A et al. (2003) Nitrobenzene toxicity: QSAR correlations and mechanistic interpretations. J Phys Org Chem 16:811–817
89. 1A receptor ligands from crystallographic data. Updated model of the receptor pharmacophore. Archiv der Pharmazie 330:146–160
90. Hibert MF, Gittos MW, Middlemiss DN et al. (1988) Graphics computer-aided receptor mapping as a predictive tool for drug design: Development of potent, selective, and stereospecific ligands for the 5-HTlA receptor. J Med Chem 31:1087–1093
91. Hibert MF, Mcdermott I, Middlemiss DN et al. (1989) Radioligand binding study of a series of 5-HT1A receptor agonists and definition of a steric model of this site. Eur J Med Chem 24:31–37
92. Kuz’min VE, Polischuk PG, Artemenko AG et al. (2008) Quantitative structure–affinity relationship of 5 HT1A receptor ligands by the classification tree method. SAR & QSAR in Env Res 19:213–244
93. Todeschini R, Consonni V (2000) Handbook of molecular descriptors, 1st ed. Wiley-VCH, Weinheim
94. Artemenko AG, Kuz’min VE, Muratov EN et al. (2009) The analysis of influence of benzodiazepine derivatives structure on its pharmacocinetic properties. Khim-Pharm Zhurn 43:36–45 (in Russ)